Study on the Efficacy and Quality of Life Impact of Combination Adjuvant Chemotherapy with Epirubicin and Docetaxel for Breast Cancer Patients after Radical Mastectomy

Objective: To explore and analyze the clinical effect of combination adjuvant chemotherapy with epirubicin and docetaxel for patients after radical mastectomy for breast cancer. Methods: This study enrolled 60 patients between May 2022 and December 2024, who were randomly allocated into two equal treatment groups (n = 30 each). The control group received standard chemotherapy, whereas the observation group was treated with a combined adjuvant regimen of epirubicin and docetaxel. Therapeutic outcomes were systematically compared between the groups. Results: The comparative analysis of chemotherapy regimens revealed significant intergroup differences in multiple outcome measures. The observation group demonstrated superior clinical efficacy (96.67% vs 80.00%, P < 0.05) alongside a more favorable safety profile (adverse reaction incidence: 3.33% vs 20.00%, P < 0.05). Metabolic assessments showed better glycemic control in the observation group, with both fasting and postprandial blood glucose levels being significantly lower than controls (P < 0.05), while maintaining comparable values to pretreatment baselines (P > 0.05). Furthermore, quality of life assessments indicated significantly better outcomes in the observation group compared to controls (P < 0.05). Conclusion: The combination of epirubicin and docetaxel as adjuvant chemotherapy for patients after radical mastectomy for breast cancer has significant clinical effects, can improve patients’ quality of life, and has high safety. It is worthy of adoption.